Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...
A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...
The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...
Hosted on MSN
Engineered T-cells use natural receptors as 'brakes' to target cancer while sparing healthy tissue
A team of researchers has successfully created more effective immune cells that can fight cancer without damaging healthy tissue. "This story goes back nearly 20 years," says Prof. Paul François. This ...
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...
As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout. When AstraZeneca scooped up the company back in 2022, ...
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names (USAN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results